Latest Healthcare News

CSL has appointed ViiV Healthcare CEO Deborah Waterhouse to lead the biopharmaceutical group from 1 February 2027. Her arrival comes with a substantial UK-pound-denominated remuneration package and a mandate to renew the pipeline while simplifying operations.

Cleo Diagnostics’ prototype ovarian cancer screening test met or exceeded every predefined performance target in a 247-person proof-of-concept study, including among 62 Stage I cases. The result moves the program into larger bridging and expanded studies, but it remains retrospective evidence rather than a validated screening test.

Telix reported US$245 million in unaudited third-quarter revenue, with Precision Medicine sales up 30% and full-year revenue and other income still expected to exceed US$1 billion. The quarter also advanced the proposed US$1.65 billion ITM merger, added FDA-approved Pixclara to the commercial portfolio and narrowed the R&D spending range.

Sigma Healthcare has entered FY27 with double-digit Chemist Warehouse sales growth, stronger earnings and a merger integration program targeting $100 million in annual synergies by FY29. The next test is whether store expansion and technology consolidation can convert momentum into durable cash returns.

Recce Pharmaceuticals says a review of blinded Phase 3 data for its RECCE 327 Gel showed strong efficacy and a positive safety profile. An independent committee is expected to assess unblinded data from 75 patients as soon as mid-November, while recruitment continues.

Rua Bioscience has raised approximately NZ$1.0 million through its rights offer, well short of the NZ$2.8 million sought. The medicinal cannabis company says it still needs more working capital to fund inventory for its UK expansion.

Ramsay Health Care’s proposed separation of its 52.79% Ramsay Santé stake has reached a key regulatory milestone, with ASIC registering the Demerger Booklet. Shareholders will vote on the transaction on 24 November, but approval remains only one step in a process that could create two separately traded healthcare exposures.

ECS Botanics has delivered a fifth consecutive quarter of positive operating cash flow, while branded sales and international expansion continue to reshape the business. The next test is whether planned UK and Polish launches can convert into recurring revenue.

Pacific Edge has secured new US payer access and a Veterans Administration purchasing agreement while proposed Medicare price increases could materially lift revenue per test. The recovery remains unfinished, however, with US commercial volumes down 13% and final Medicare coverage still pending.

Genetic Signatures says its existing directors will resign if BCAL nominees become a majority after the 28 October EGM. The company is also demanding clarity on whether BCAL intends to merge with GSS, pointing to the stark difference between the two companies’ cash runways.

Ramsay Health Care has cleared the first legal step towards distributing its 52.79% stake in Ramsay Générale de Santé to shareholders. The proposed demerger now goes to consecutive shareholder meetings on 24 November, backed by the board and Deloitte’s independent expert.

Vitura Health grew FY2026 revenue 6% to $131.2 million, but a sharp margin squeeze pushed the ASX-listed digital health company into a $4.4 million statutory loss. With ANZ debt classified as current and a potential $6 million FY2027 revenue hit from changed Bupa referrals, the promised turnaround faces a demanding test.